JUICE Pharma Worldwide was in Chicago to report on the proceedings of the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting. Medical Director Florian Brey, MD, and the JUICE team share the latest developments and research advances in cancer treatment.
Anne Davison reports on the growing enthusiasm around checkpoint inhibitors as they evolve from promising to a commercialized reality:
“There’s so much happening on the convention floor this year at ASCO. The energy is palpable. It’s clearly a convergence of oncologists and industry, science and education. What I found most interesting were the exhibitors communicating information about the new checkpoint inhibitors. Only 3 years ago at ASCO the first data was revealed for the PD-1 pathway blockade. Dr. Suzanne Topalian addressed the audience by saying that these new treatments represented a sunrise moment in oncology.
This year there’s no less enthusiasm for the data, as the benefits of these treatments continue to unfold in the scientific sessions. And we’re now seeing commercialization of these game-changers on the exhibitor floor. The approach of industry and oncology is noteworthy. There is recognition and declaration of the importance of an unwavering commitment to improving outcomes and quality and value of care for patients.”